Health AI Central
Share:
Peer-Reviewed Publication
Clin Cancer Res2026April 17, 2026Journal Article

Predictors of Immune Checkpoint Blockade Response in dMMR Colorectal Cancer Using an Integrated Immune-Enhanced Multi-Omics Platform.

Frank A Sinicrope1, Nalin Sharma2, Md Mohiuddin2, Bahar Saberzadeh-Ardestani2, Rondell P Graham3, Jason T Lewis4, Bailiang Li5, Charles W Abbott6, Sean M Boyle7
1Mayo Clinic Rochester, MN United States.
2Mayo Clinic Rochester, Minnesota United States.
3Mayo Clinic College of Medicine Rochester, MN United States.
4Mayo Clinic Jacksonville, Florida United States.
5Personalis Fremont, California United States.
6Personalis (United States) Fremont, California United States.
7Personalis (United States) Menlo Park, California United States.
PubMed PMC DOI PDF

Abstract

PURPOSE: Immune checkpoint blockade (ICB) induces frequent and durable responses in metastatic dMMR CRC, yet substantial molecular heterogeneity and resistance remain. We sought to identify candidate tumor- and immune-related biomarkers associated with clinical outcomes following anti-PD-1 therapy. METHODS: Consecutive patients with metastatic dMMR CRC (N=39) treated with anti-PD-1 therapy underw…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.